Autopsy report · NCT05542355

EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

“Due to low recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 1 year 6 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Exeliom Biosciences

Sponsor type

Industry

Conditions

Crohn Disease

Interventions

EXL01; Placebo; SoC corticosteroid - Induction Period; SoC corticosteroid - Tapering

Participants

8

Sites

5

Countries

Belgium, Poland

Trials that died the same way

• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
  “Due to Poor Recruitment” (95% match in meaning)
• REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia
  “Because of low recruitment” (94% match in meaning)
• BicepsTenodesis vs. Biceps Debridement in Combined RC Tears and SLAP Lesions
  “Due to low recruitment rate” (93% match in meaning)
• Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas
  “due to lack of recruitment” (92% match in meaning)
• Robotic Therapy and Transcranial Direct Current Stimulation in Patients With Stroke
  “Because of low recruitment rates” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.